MMMarina Nikolayevna Makarova

Marina Nikolayevna Makarova

*This is an algorithmically generated author record based on publicly available information.

Marina Nikolayevna Makarova has a total of 248 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    On the Question of Sample Size Planning in Bioequivalence Studies from the Perspective of Desired Statistical Power

    by V. M. Kosman, M. V. Karlina, M. N. Makarova, V. G. Makarov, В. М. Косман, М. В. Карлина, М. Н. Макарова, В. Г. Макаров

    INTRODUCTION. The sample size (number of volunteers or target animals) is a significant element of in vivo bioequivalence (BE) studies; however, the algorithm for its calculation is not specified in regulatory documents. Increasing the sample size beyond the minimum allowable number may be unethical and lead to unreasonable financial costs. AIM. This study aimed to review scientific approaches to justifying the sample size in bioequivalence studies from the perspective of the desired statistical power and to retrospectively evaluate our own experiments to improve the planning of such studies. MATERIALS AND METHODS. The study analyzed regulatory documents of the Eurasian Economic Commission, the Ministry of Agriculture of Russia, scientific publications and other open-access sources. Using the intra-individual coefficient of variation (CV intra ) and RStudio software, we estimated the statistical power of the performed studies for the pharmacokinetic parameters maximum concentration (C max ) and area under the concentration-time curve (AUC) and calculated the sample size required to achieve a power of at least 80% (if this power level was not achieved). RESULTS. The use of an evidence-based approach to sample size estimation using CV intra (for crossover design studies) or the coefficient of total variation (CV total ) (for parallel design studies) is limited by the lack of a unified calculation algorithm and insufficient available data on previous BE studies. A retrospective evaluation of BE studies conducted with our participation revealed that in many cases, the recommended power level was not achieved. For low-molecular-weight-heparin (LMWH) products for human medical use, the calculated sample size was up to 100 or more subjects, while for veterinary drugs, it ranged from 14–18 to 50–80 animals. CONCLUSIONS. To correctly estimate the sample size when planning clinical trials of LMWH products, which may be highly variable, it is advisable to accumulate data on the CV intra parameter and to consider two-stage (adaptive) designs. Increasing the sample size and introducing adaptive designs for veterinary medicinal products may lead to an unjustified increase in study duration and cost and to the market introduction of such products. Therefore, analysis and comprehensive discussion of the planning of preclinical and clinical studies of veterinary medicinal products are advisable.

  • Open Access

    Data variability in rats depending on housing and breeding conditions. Acceptability criteria for biological test systems

    by A. E. Katelnikova, M. A. Akimova, M. N. Makarova, V. G. Makarov, M. A. Kovaleva, E. A. Shamray, A. Yu. Pereboeva, A. S. Ivkina, D. Yu. Ivkin, А. Е. Кательникова, et al.

    Background. The reliability and reproducibility of preclinical in vivo studies significantly depend on the quality of laboratory animals. Objective. To compare the variability of clinical laboratory and behavioral parameters, as well as the level of microbiological control, in rats obtained from four breeding facilities located in the Russian Federation. Materials and Methods. This paper presents coefficient of variation (CV %) values for complete blood count parameters, biochemical analysis parameters (alanine aminotransferase, aspartate aminotransferase (AST), creatinine, lactate dehydrogenase (LDH), total protein, urea), and hemostasis system parameters (activated partial thromboplastin time and prothrombin time), respiratory rate, and behavioral test parameters (number of rearings against the walls and number of squares visited). The study included 4 groups of 10 males and 10 females each. Results. Based on the data analysis, elevated leukocyte levels were detected in the blood of animals without SPF status; in group 1, rats showed deviations outside the reference intervals for creatinine (20 % higher in males and 7 % higher in females), urea (20 % higher in males and 12 % higher in females), and AST. The coefficient of variation for most parameters was below 20 %, indicating satisfactory homogeneity. High interindividual variability (CV > 20–30 %) was observed only for lactate dehydrogenase (LDH) and behavioral tests. A sex difference was observed: in males, the CV values for leukocyte count and differential leukocyte count ranged from 10 % to 20 %, whereas in females the CV exceeded 20 % in all groups. Respiratory rate and hemostasis parameters showed low biological variability in all groups. Conclusion. The variability of the studied parameters was not influenced by the source of the animals; rather, the method used to analyze the parameter was significant. An attempt was made to define acceptability criteria for variability of major vital parameters in biological test systems. For example, variability with CV < 5 % can be regarded as “too” low (high data homogeneity); CV < 10 % corresponds to low variability (homogeneous data); CV from 10 to 20 % indicates satisfactory variability (data homogeneity acceptable for most parameters); CV from 20 to 30 % reflects moderate variability (data with considerable scatter typical for biological test systems); and CV > 30 % indicates high variability (heterogeneous dataset).

  • Open Access

    Approaches to Drug Pharmacokinetics Study Design in Preclinical Trials (Review)

    by M. V. Karlina, V. M. Kosman, M. N. Makarova, V. G. Makarov

    INTRODUCTION . According to drug registration requirements, a registration dossier should include the data on preclinical trials of drug pharmacokinetics. However, the scope of data provided for various drugs groups, as well as pharmacokinetics elements to be studied at each stage of the product life cycle is still a relevant issue. AIM . This study aimed to analyze literature data, Russian and foreign guidelines on preclinical trials of drug pharmacokinetics to choose an optimal strategy of data collection at various stages of drug life cycle. DISCUSSION . The research materials included regulatory documents, guidelines on preclinical trials, scientific articles and other publicly available sources (including electronic RSCI databases (eLIBRARY.RU), PubMed, and Web of Science). We analyzed the main approaches to planning pharmacokinetic trials for various drugs (original, generic, biological drugs, etc.), including the type and number of laboratory animals, the doses studied and the time points of biomaterial sampling. CONCLUSIONS . Preclinical pharmacokinetic trials are warranted for optimization of active pharmaceutical substance molecules, selection of the dosage form to study various drug groups, predicting pharmacokinetic parameters in humans, reducing time costs and risks when developing safe and effective drugs. Designs of pharmacokinetic trials were proposed at the stage of molecule screening, molecule optimization and selection of the drug forms for the research of various drug groups.

  • Open Access

    Intraocular pressure reference intervals in different laboratory animal species

    by A. A. Golovina, А. Е. Кательникова, M. N. Makarova, V. D. Karanina

    Ophthalmotonometry is a non-invasive method for recording intraocular pressure (IOP) and is widely used in preclinical studies for the early detection of toxic effects and a comprehensive assessment of the pharmacological activity of drugs. This article presents the reference intervals for intraocular pressure in cynomolgus macaques, dwarf pigs, rats, and Pannon and Soviet Chinchilla rabbits. The reference intervals were obtained from healthy cynomolgus macaques (n=50), Wistar rats (n=80), dwarf pigs (n=36), Soviet Chinchilla (n=80), and White Pannon (n=62) rabbits at JSC NPO DOM PHARMATII between May 2024 and July 2025. Measurements were performed in sexually mature and immature males and females (non-pregnant and nulliparous, ignoring the estrous cycle phase). Measurements were performed using a TonoVet veterinary tonometer on male and female laboratory animals of various ages. The smallest variation in individual IOP values was observed in Soviet Chinchilla and White Pannon rabbits, not exceeding 10.5%. The vast majority of studies published in experimental ophthalmology use New Zealand albino rabbits (a New Zealand breed). However, excluding animals with melanin-containing eyes significantly reduces the translational value of the research, as most humans have pigmented eyes. These results can be used in preclinical drug toxicity studies, in assessing the pharmacological activity of antihypertensive drugs in in vivo glaucoma models, and in diagnosing diseases in exotic animals.

  • Open Access

    Comparison of methods for assessing the immunogenicity of biological drugs based on monoclonal antibodies using the example of pembrolizumab

    by Valeriia S. Chernyshenko, Natalia M. Faustova, Vera M. Kosman, Marina V. Karlina, Anna Yu. Romanenko, Marina N. Makarova, Valery G. Makarov, Anastasia A. Dmitrieva, Elena V. Shipaeva, Mikhail G. Chernobrovkin, et al.

    Background. To ensure the safety and effectiveness of biological drugs, it is critically important to evaluate their immunogenicity. The most commonly used enzyme-linked immunosorbent assay (ELISA) has a number of limitations, so it is important to understand the possibilities of alternative approaches, for example, the biolayer interferometry (BSI) method. Aim. Development, validation and comparison of two methods for screening assay in the context of assessing the immunogenicity of biological drugs based on monoclonal antibodies using the example of pembrolizumab with multiple intravenous administration to Macaca fascicularis. Materials and methods. Immunogenicity was evaluated as part of a comparative study of toxicity and local tolerance of two drugs with International Nonproprietary Name pembrolizumab following repeated administration. Macaca fascicularis (3 groups of 3 males and 3 females in each) on days 1, 8, 15 and 22 of the experiment received intravenously a control substance (buffer solution), test drug (RPH-075, JSC R-Pharm, Russia) and reference drug (Keytruda®, MSD International GmbH, Ireland) at a dose 30 mg/kg. Serum samples, were collected pre-dose and on study days 15, 22, 29, and were tested for assessment of binding antibodies to pembrolizumab using two methods, bridging ELISA and BSI. Results. During the development and testing of methods for binding antibodies (BAb) to pembrolizumab quantification in monkey’s blood serum of by the bridge ELISA and BSI assays, it was revealed that the bridge ELISA has greater sensitivity (12.3 and 419.7 ng/mL, respectively). Determination of BAb level to pembrolizumab by ELISA revealed immunogenicity in 4 out of 12 animals; when analyzing samples by BSI, an increasing of BAb concentration was detected in only one animal. Conclusion. Bridging ELISA is more sensitive than BSI making it the preferred method for assessing of drugs with unknown or suspected low immunogenicity.

  • Open Access

    Application of human-specific ELISA kits for the analysis of laboratory animal biomaterial

    by N. M. Faustova, V. M. Kosman, M. V. Karlina, M. N. Makarova, V. G. Makarov

       Background.  Enzyme-linked immunosorbent assay (ELISA) is widely used in the study of pharmacological safety, pharmacokinetics, pharmacodynamics of both original and reproduced (biosimilar) drugs; it is the method of choice for the evaluation of various biomarkers in clinical and preclinical studies. A feature limiting the use of this method is its species specificity.    Objective.  The article discusses the use and adaptation of ELISA sets specific for humans for the analysis of biomaterial from laboratory animals.  Design and methods.  The materials of several studies performed in the organization using rats as one of the most common test systems in preclinical studies, and including the use of ELISA kits for the determination of steroid hormones in the blood (testosterone, estradiol), stress hormones (cortisol, corticosterone) and cardiac biomarkers (myoglobin, troponin).    Results.  Examples of using reagent kits without any changes are shown (cortisol), after various optimization options (corticosterone, testosterone, estradiol). On the myoglobin cardiomarker example an algorithm for biomaterial type choosing is presented, which allows expanding the initial field of reagent kit use and unifying the biomaterial selection in an experimental study, and troponin I turned out to be an example of the unsuitability of the kit for analyzing rat biomaterial.    Conclusion.  Based on experimental experience, an algorithm and decision-making scheme for approbation and adaptation of ELISA reagent kits specific for humans in the analysis of laboratory animal biomaterial are formulated.

  • Open Access

    Orthotopic models in cancer research: a literature review. To the 150th anniversary of the first successful serial tumor transplantation in animals

    by Ia. G. Murazov, M. A. Kovaleva, K. L. Kryshen, M. N. Makarova, V. G. Makarov

    Background. Transplantation models, including allografts and xenografts are crucial in oncology research because they help study the mechanisms of carcinogenesis and assess the activity of promising antitumor agents. Objectives : 1) to conduct a traditional analysis of scientific literature devoted to orthotopic transplantation in laboratory animals using various sources of tumor material, 2) to describe the main advantages and limitations of orthotopic models, 3) to provide practical recommendations for researchers dealing with orthotopic transplantation models. Material and Methods . A search was conducted in PubMed and Google Scholar bibliographic databases. The review included relevant publications available for search until April 30, 2025. Results . Compared to transplantation of tumor cell suspensions cultured in vitro, transplantation of solid tumor fragments ensures preservation of the clonal heterogeneity of the tumor, components of its microenvironment and extracellular matrix, which support engraftment and tumor growth. Compared to subcutaneous transplantation, orthotopic models offer a more realistic depiction of the complex interactions in the tumor-host system and the pathological characteristics of human cancers, particularly those involving metastasis. Because orthotopic tumors exist within their natural environment, the evaluation of their response during preclinical research is more likely to be translatable in the initial phases of clinical trials. Conclusion. Incorporating orthotopic models into non-clinical in vivo pharmacodynamic research programs improve the predicitve value and dependability of preclinical results and offer a chance to gain a more thorough understanding of the antitumor activity of the experimental treatment.

  • Open Access

    Pharmacokinetic assessment of two IgG1 kappa monoclonal antibodies neutralising the SARS-CoV-2: A study in Syrian hamsters and ICR CD1 outbred mice

    by T. N. Barybina, N. M. Faustova, M. V. Karlina, V. M. Kosman, P. P. Solodkov, S. V. Kulemzin, M. N. Makarova, V. G. Makarov

    INTRODUCTION . Еvaluation of pharmacokinetics of monoclonal antibodies (mAb) products requires careful selection of the relevant animal models to ensure translational relevance of the data. To solve this problem, the pharmacokinetic parameters of two human monoclonal antibodies neutralising SARS-CoV-2 were evaluated in two types of laboratory animals — Syrian hamsters and mice. AIM . This study aimed to evaluate the pharmacokinetic parameters of two different human IgG1 kappa antibodies (mAb iC1 and mAb iB20) neutralising SARS-CoV-2 after a single intravenous administration to Syrian hamsters and ICR CD1 outbred mice. MATERIALS AND METHODS . A pilot study was performed on 15 male Syrian hamsters who received a single 5 mg/kg intravenous dose of mAb iC1. Blood samples were collected prior to administration and at 10 time points for 144 hours. In the main study, ICR CD1 mice (4 groups of 60 animals) received single intravenous doses of mAb iC1 and mAb iB20 at doses of 5 and 50 mg/kg. Blood samples were collected prior to administration and at 11 time points for 504 hours. Serum antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA). The ELISA assay was validated by following parameters: selectivity, lower limit of quantitation, calibration range, accuracy, precision, and analyte stability. Pharmacokinetic parameters — mean maximum concentration (C max ), area under the curve (AUC 0–t ), mean residence time (MRT), half-life (T 1/2 ), and clearance (Cl) — were calculated using model-independent method of statistical moments. RESULTS . The ELISA assays for mAb iC1 and mAb iB20 in animal blood serum were validated in the analytical range of 1.25–25.0 μg/mL and 1.25–20.0 μg/mL, respectively. C max , AUC 0–t , and AUC 0–∞ increased significantly with the dose for both antibodies. After administration of 5 and 50 mg/kg mAb iC1 to mice the mean C max values were about 235 and 1228 μg/mL, AUC 0–t — 6458 and 71,193 h×μg/mL. For mAb iB20 C max values were about 359 and 4442 μg/kg, AUC 0–t — 6344 and 76,251 h×μg/mL, respectively. MRT and T 1/2 values did not depend on the administered dose. Combined with low clearance values, this indicates long-term presence of analytes in the bloodstream. CONCLUSIONS . Pharmacokinetic parameters of mAb iC1 and mAb iB20 were determined after single administration to Syrian hamsters and ICR CD1 mice. Key parameters (C max , AUC 0–t ) were found to be dose-dependent. The obtained results can be used for further preclinical and clinical development of the medicinal products.

  • Open Access

    Ketoprofen Comparative Pharmacokinetics Analysis in Humans and Animals: A Review

    by E. M. Petrova, V. M. Kosman, M. V. Karlina, M. N. Makarova, V. G. Makarov

    INTRODUCTION . Ketoprofen is a non-steroidal anti-inflammatory drug (NSAID) with pronounced analgesic, anti-inflammatory and antipyretic effect. Ketoprofen pharmacokinetics is comparatively well described in various in vivo models. Since it is potentially possible to create new dosage forms of ketoprofen, with pharmacokinetics studies contributing to high-quality pharmaceutical development, a comparative assessment is relevant for the data on animals and humans. AIM. This study aimed to identify animal species relevant for preclinical studies of different ketoprofen dosage forms by summarising bioanalytical methods used to assess pharmacokinetics and by comparing various test systems. DISCUSSION . Reversed-phase high-performance liquid chromatography with ultraviolet/mass spectrometric detection and acetonitrile or methanol-based eluents in various buffer solutions is the most ubiquitous method for ketoprofen analysis in biomaterials. Ketoprofen pharmacokinetics was studied in humans and animals of several phylogenetic species using various dosage forms (injectable solutions, tablets, paste forms, etc.) and the relevant administration (intravenous, intramuscular, oral, transdermal). High drug bioavailability was noted for different routes. Maximum concentration (C max ) range at similar doses and similar time parameters (time to maximum concentration, T max , half-life, T 1/2 and mean residence time, MRT) for the three main administration routes (oral, intravenous and intramuscular) was comparable in humans and rats, cats, and dogs; thus these test systems were suggested for pharmacokinetics studies of ketoprofen preparations. CONCLUSIONS . The analysis suggested that rats and larger animals (cats, dogs) can serve as test systems in ketoprofen pharmacokinetics studies, at least for oral, intravenous, and intramuscular administration. Using ketoprofen as an example, the study showed feasibility of integrating heterogeneous pharmacokinetic data, as well as comparison challenges due to variable test systems, study objects, dosages, and administration routes.

  • Open Access

    Validating Bioanalytical Methods for Biomarker Quantitation: A Regulatory Document Review

    by V. M. Kosman, M. V. Karlina, N. M. Faustova, M. N. Makarova, V. G. Makarov

    INTRODUCTION. Biomarkers are used to assess normal physiological processes in the body; to diagnose and select therapy for various diseases; and to develop new drugs. The increasing use of biomarkers as drug development tools necessitates improvements in analytical quantification methods. AIM. This study aimed to review and summarise data on validation of bioanalytical methods for biomarker quantification. DISCUSSION. The analysed regulatory documents were issued by International Council for Harmonisation (ICH), as well as Food and Drug Administration (FDA), including the Biomarker Assay Collaborative Evidential Considerations Writing Group and Critical Path Institute (C-Path); European Medical Agency (EMA); Eurasian Economic Commission (EEC); and other publicly available research platforms (including PubMed, Web of Science, RSCI (eLIBRARY.RU), and Google Scholar online databases) primarily published in 2014–2024. Analytical and clinical biomarker validation was examined, alongside with analytical validation stages and key validation parameters of the bioanalytical method depending on the objective (analysis for pharmacokinetics, bioequivalence, and toxicokinetics studies; biomarker analysis in drug development and for diagnosis in preclinical and clinical studies). Proposed is an algorithm for choosing biomarker analytical validation level depending on the method (chromatography, ligand-binding methods using reagent kits for various purposes) and the issues to be addressed. CONCLUSIONS. Confirming biomarker method suitability as per the objectives is similar to a common validation procedure of bioanalytical methods. A broad and detailed scientific discussion of biomarker analysis validation is needed, since a comprehensive scheme developed for this complex procedure will contribute to more reliable use of biomarkers, improved quality of studies within this process, and resulting safe and effective new medicinal products.